Navigation Links
Mayo Clinic study finds that after heart attack most patients stop taking life-saving drugs
Date:11/5/2007

ORLANDO, Fla. -- Recovery from heart attacks is best served by continuing to take prescribed medications. Yet more than half of patients who have had a heart attack stop taking these lifesaving medications within three years, according to results from a Mayo Clinic study presented today at the American Heart Associations Scientific Sessions 2007 in Orlando, Fla.

The Mayo data also show that in the short term, smokers are more likely to discontinue taking all of their prescribed heart medications, whereas in the long term, data show that patients enrolled in cardiac rehabilitation programs tend to continue their medications at a higher rate than patients who do not enroll. The researchers suggest their data support a two-pronged strategy for improving the publics heart health: 1) target heart patients who smoke for education on complying with physicians aftercare advice about continuing medications, and 2) encourage all heart patients to participate in a cardiac rehabilitation program, possibly increasing their likelihood of continuing prescribed treatments.

Significance of the Mayo Clinic Research

The study was designed to improve recovery and quality of life after heart attack by determining how well patients comply with physicians recommendations. It clearly documented that treatments exist that improve outcomes following heart attacks -- but patients need to comply with the treatment regimens for the goal of improved patient health to be realized, says Nilay Shah, Ph.D., the studys lead researcher.

By following patients at six, 12 and 36 months after a heart attack, the researchers discovered that smokers are most likely to stop taking their medication, placing them at increased risk for more heart attacks and complications, says Dr. Shah. This suggests that current smokers may be a target group for education acute heart attack. Participation in cardiac rehab programs seems to be another important factor associated with long-term continuation of prescribed medication therapy, he says.

Patients discontinue taking medications too soon for a variety of reasons, including cost, says Veronique Roger, M.D., M.P.H., co-author of the study. More research is crucial to understand and resolve the barriers patients face as they recover from heart attacks she says.

About the Study

In their study, the Mayo researchers evaluated 292 patients, a subset of all the patients who were enrolled in the Olmsted County, Minn., registry of acute heart attacks. This subset also had prescription drug claims data available from another source. The team looked at long-term data (up to 10 years) for patients who had heart attacks and who were discharged from the hospital and taking ACE inhibitors, beta-blockers and statins to help prevent another heart attack.

Results showed that:

  • At six months, smokers were significantly less likely to continue all three heart medications compared to nonsmokers.

  • At six months, 92 percent of the patients taking statins continued treatment, and by three years only 44 percent of the patients continued taking statins.

  • Similarly, the rate of beta-blocker continuation dropped from 89 percent at six months to 47 percent at three years.

  • The rate of ACE inhibitor continuation dropped from 77 percent at six months to 37 percent at three years.


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Radiologists encouraged to look beyond cancer for clinically unseen diseases
3. Clinical depression linked to abnormal emotional brain circuits
4. Preclinical study suggests organ-transplant drug may aid in lupus fight
5. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
6. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
7. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
8. MinuteClinic Becomes Participating Provider with Assurant Health
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Acupuncturists Relocation Tightens Relationship With Fertility Clinic
11. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and ... the ultimate weight loss and wellness program, at their world headquarters of Omni La ... immediate and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
(Date:12/8/2016)... ... 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 ... the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) ... Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... 2016 Research and Markets has announced the addition ... to their offering. ... The report provides separate comprehensive analytics for ... and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:12/7/2016)... -- "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by ... drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... patent on Lantus expired in 2014. Lantus is the brand name ...
Breaking Medicine Technology: